Clinical indicators of response to CD20 upregulation on tumor cells by cytokines.

被引：0
|
作者：
Subramanian, A
Venugopal, P
Baseer, S
Nirula, S
Sivaraman, S
O'Brien, TM
O'Donnell, K
Gregory, SA
Jajeh, A
Preisler, HD
机构：
[1] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA
[2] Cook Cty Hosp, Chicago, IL 60612 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4728
引用
收藏
页码：231B / 231B
页数：1
相关论文
共 50 条
  • [31] Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?
    Somasundaram, Rajasekharan
    Villanueva, Jessie
    Herlyn, Meenhard
    MOLECULAR THERAPY, 2011, 19 (04) : 638 - 640
  • [32] ABNORMAL EXPRESSION OF CD20 ON IGG4 PLASMA CELLS
    Bakke, Antony C.
    Grimm, Kate
    O'Malley, Dennis P.
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2012, 82B (05) : 326 - 326
  • [33] High, stable and homogenous CD20 expression for efficient rituximab-induced elimination of CD20+ alloreactive donor T cells in the novel CD20/Rituximab 'suicide' system
    van Meerten, T
    Claessen, MJ
    Hagenbeek, A
    Ebeling, S
    BLOOD, 2004, 104 (11) : 485A - 485A
  • [34] Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells
    Kozlova, Veronika
    Ledererova, Aneta
    Mancikova, Veronika
    Mayer, Jiri
    Pospisilova, Sarka
    Doubek, Michael
    Smida, Michal
    LEUKEMIA & LYMPHOMA, 2020, 61 : 256 - 257
  • [35] Genetic modification of human T cells with CD20: A strategy to purify and lyse transduced cells with anti-CD20 antibodies
    Introna, M
    Barbui, AM
    Bambacioni, F
    Casati, C
    Gaipa, G
    Borleri, G
    Bernasconi, S
    Barbui, T
    Golay, J
    Biondi, A
    Rambaldi, A
    HUMAN GENE THERAPY, 2000, 11 (04) : 611 - 620
  • [36] Epigenetic Drug Screen on Resistant CLL Cells Reveals Aurora Kinase Inhibitors As Enhancers of CD20 Expression and Sensitizers to Treatment with CD20 Monoclonal Antibodies
    Kozlova, Veronika
    Ledererova, Aneta
    Doubek, Michael
    Mayer, Jiri
    Pospisilova, Sarka
    Smida, Michal
    BLOOD, 2018, 132
  • [37] Identification of CD20 mutations in malignant lymphoma: Can they be predictors of response to rituximalb?
    Terui, Y
    Sakurai, T
    Mishima, Y
    Mishima, Y
    Sugimura, N
    Kojima, K
    Yokoyama, M
    Hatake, K
    BLOOD, 2005, 106 (11) : 88A - 88A
  • [38] INTRA-CYTOPLASMIC CYTOKINES IN CD20 POSITIVE LYMPHOCYTE SUBPOPULATIONS IN RHEUMATOID ARTHRITIS (RA) PATIENTS
    Aamar, S.
    Kerpel, A.
    Rabinowitz, R.
    Levy, P.
    Zelig, O.
    Schlesinger, N.
    Schlesinger, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 268 - 268
  • [39] CD20 mAb-Mediated Complement Dependent Cytotoxicity of Tumor Cells is Enhanced by Blocking the Action of Factor I
    Lindorfer, Margaret A.
    Beum, Paul V.
    Taylor, Ronald P.
    ANTIBODIES, 2013, 2 (04): : 598 - 616
  • [40] Restoration of rituximab sensitivity in CD20 negative B-Cell lymphoma, cells; Epigenetic change of CD20 expression after treatment of rituximab.
    Tomita, Akihiro
    Hiraga, Junji
    Kiyoi, Hitoshi
    Kinoshita, Tomohiro
    Naoe, Tornoki
    BLOOD, 2006, 108 (11) : 155B - 155B
12345